文献速递肝病消化道肿瘤与早癌

胰高血糖素样肽-1受体激动剂与2型糖尿病患者肝细胞癌发生率及肝功能失代偿的关联

Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.
PubMed 文献 · Gastroenterology · 2024-04-29

这项回顾性队列纳入1,890,020例2型糖尿病患者,比较使用胰高血糖素样肽-1受体激动剂(GLP-1RA)与其他非GLP-1RA降糖药者的肝细胞癌(HCC)新发诊断与肝功能失代偿事件。GLP-1RA与胰岛素、磺脲类、二甲双胍相比的HCC风险比分别为0.20、0.39、0.63;与6种其他降糖药相比,肝功能失代偿风险显著更低。作者认为这些发现为未来研究其机制与临床应用提供了支持证据。

要点

  • GLP-1RA与胰岛素相比HCC风险比为0.20,与磺脲类相比为0.39,与二甲双胍相比为0.63。
  • GLP-1RA与6种其他降糖药相比,肝功能失代偿风险显著更低。
  • 无肝病者中效应更明显,肥胖及酒精或烟草使用障碍者中观察到相似结果。

核心结论

  • 在2型糖尿病患者中,与其他降糖药相比,GLP-1RA与新发HCC及肝功能失代偿风险降低相关。
  • 作者认为这些发现为未来研究其潜在机制和临床应用提供了支持证据。

研究设计与样本

  • 回顾性队列研究,纳入1,890,020例确诊2型糖尿病、处方GLP-1RA或其他非GLP-1RA降糖药且既往无HCC诊断的患者。
  • 比较处方GLP-1RA与其他降糖药队列在5年随访期间HCC首次诊断及肝功能失代偿事件。
  • 采用Kaplan-Meier生存分析进行至首次事件时间分析,并计算风险比与95%CI。

主要发现

  • GLP-1RA与胰岛素相比HCC风险比为0.20(95%CI 0.14-0.31)。
  • GLP-1RA与磺脲类相比HCC风险比为0.39(95%CI 0.21-0.69)。
  • GLP-1RA与二甲双胍相比HCC风险比为0.63(95%CI 0.26-1.50)。
  • GLP-1RA与6种其他降糖药相比,肝功能失代偿风险显著更低。
  • 无肝病及不同分期脂肪性肝病患者中均观察到风险降低,无肝病者效应更明显;肥胖及酒精或烟草使用障碍者中结果相似;联合治疗较单药治疗与HCC及肝功能失代偿风险降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC is preventable with about 70% of HCC attributable to modifiable risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), Food and Drug Administration-approved medications for treating type 2 diabetes mellitus (T2DM), have pleiotropic effects on counteracting risk factors for HCC. Here we evaluate the association of GLP-1RAs with incident HCC risk in a real-world population. METHODS: This retrospective cohort included 1,890,020 patients with a diagnosis of T2DM who were prescribed GLP-1RAs or other non-GLP-1RA anti-diabetes medications and had no prior diagnosis of HCC. Incident (first-time) diagnosis of HCC and hepatic decompensating events during a 5-year follow-up was compared between cohorts of patients prescribed GLP-1 RAs vs other anti-diabetes medications. Time-to-first-event analysis was performed using Kaplan-Meier survival analysis with hazard ratio and 95% confidence interval calculated. RESULTS: GLP-1RAs were associated with a lower risk of incident HCC with hazard ratio of 0.20 [0.14-0.31], 0.39 [0.21-0.69], 0.63 [0.26-1.50] compared with insulin, sulfonylureas, and metformin, respectively. GLP-1RAs were associated with a significantly lower risk of hepatic decompensation compared with 6 other anti-diabetes medications. Reduced risks were observed in patients without and with different stages of fatty liver diseases, with more profound effects in patients without liver diseases. Similar findings were observed in patients with and without obesity and alcohol or tobacco use disorders. GLP-1RA combination therapies were associated with decreased risk for HCC and hepatic decompensations compared with monotherapies. CONCLUSIONS: GLP-1RAs were associated with a reduced risk of incident HCC and hepatic decompensation compared with other anti-diabetes medications in patients with T2DM. These findings provide supporting evidence for future studies to investigate the underlying mechanisms and their clinical use.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wang L, Berger NA, Kaelber DC, et al. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes. Gastroenterology. 2024. PMID: 38692395. doi:10.1053/j.gastro.2024.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。